Abeona Therapeutics reported a third-quarter loss of $0.08 per share, beating the -$0.14 consensus by 42.9% and improving 20.0% from a year ago. The revenue line is the real story. Net ZEVASKYN sales of $13.49 million missed the $18.07 million consensus by 25.3%. That miss matters more than the EPS beat because ZEVASKYN is still a young launch, and investors value it on the slope of its adoption curve. Revenue grew 18% sequentially, from $11.4 million. That still counts as growth, but it slowed from 31% in the second quarter. The ramp is continuing, just not at the pace the Street had modeled.

The quality of the earnings beat deserves scrutiny. The net loss narrowed to $4.8 million from $20.2 million in the second quarter. However, $6.5 million of the improvement came from a non-cash gain on the fair value of warrant liabilities. On an operating basis, the loss was $13.0 million, compared with $24.0 million a year earlier, when there was no product revenue. Underlying cost trends were mixed:

• Cost of sales rose to $5.7 million from $4.2 million.
• Implied gross margin fell to roughly 58% from about 63%, which is far below the 85-90% steady-state target that management only reiterated.
• R&D dropped to $3.7 million from $5.0 million.
• SG&A climbed to $17.1 million.

The headline beat owes more to below-the-line accounting and lighter R&D than to commercial leverage.

The call showed real operating progress alongside a softer near-term setup. On the positive side:

• Revenue-recognized treatments rose to five from four in Q2 and three in Q1.
• The qualified treatment center (QTC) network reached eight sites, beating the original goal of seven by year-end.
• Four centers have now treated patients, up from two, after Children's Hospital of Philadelphia and the University of Texas Medical Branch completed their first cases.
• The reimbursement framework is largely in place: about 95% commercial coverage, baseline Medicaid coverage in all 50 states, and NTAP effective October 1.

The negatives were also concrete:

• For the second straight quarter, a batch could not be billed. This time it was an identity-assay out-of-spec lot, after Q2's low-yield lot.
• The expansion to 10 manufacturing slots per month slipped to mid-2027 from earlier talk of the second half or end of 2026. Staff for the added suites has not yet been hired.
• Biopsy collection pauses from mid-November to mid-January for the annual shutdown, which truncates both Q4 2026 and Q1 2027.
• Earlier talk of monthly profitability starting around June 2026 was not referenced at all.
• Management still declines to disclose funnel or biopsy metrics, which limits visibility into demand.

The central tension is strategic. Management repeated that ZEVASKYN is its "number one priority," yet the quarter's biggest announcement was a diversification move. Abeona acquired APT-1011, now ABO-801, a Phase 3-ready oral fluticasone tablet for eosinophilic esophagitis. Terms include:

• $20 million in stock and no upfront cash;
• $30 million due on FDA approval;
• up to $30 million in sales milestones;
• low-to-mid-teen royalties.

Management plans a roughly 400-patient Phase 3 starting mid-2027, with topline data around the end of 2028 and $50-60 million in development costs to approval. It claims peak sales potential above $750 million. Bears have legitimate ammunition here. Both prior Phase 3 trials missed the symptom co-primary endpoint, the new case rests on post-hoc symptom-questionnaire mapping, and whether a single trial would suffice has not been confirmed in writing. A $30 million PIPE accompanied the deal, adding dilution on top of the stock paid to Ellodi. Cash fell to $134.9 million from $146.8 million, and that figure excludes the PIPE proceeds. A more favorable optionality item is Ultragenyx's FDA approval of FAYUVI, which makes Abeona eligible for commercial milestones and royalties of up to 8%.

The market had already turned skeptical before the print. Earnings Whispers investor sentiment swung from a solidly positive 0.49 after the prior report to a slightly negative -0.08, a substantial deterioration. Shares fell 31.5% from the $6.09 open after the August report to $4.17. That leaves them about 24% below the 200-day moving average and only 6.6% above the 52-week low of $3.91, set on November 5. Price and AVWAP trend readings are both negative, consistent with a stock that has been sold steadily through the quarter rather than in a single shock.

The bottom line is that Abeona's EPS beat is the least informative number in the release. ZEVASKYN is still growing, the treatment-center footprint is broadening, and reimbursement is largely solved. However, revenue fell well short of expectations and sequential growth slowed. Margins moved the wrong way, manufacturing reliability remains a recurring issue, capacity timelines slipped, and the next two quarters face a known seasonal gap. Layering a dilutive, clinically uncertain EoE program onto that backdrop explains why investors have grown more cautious. The near-term debate will hinge on whether treatment volumes and batch success can re-accelerate once biopsies resume in January.